Disclosed are methods of forming articles from magnesium alloys using additive manufacturing (e.g., binder jet additive manufacturing) that involve a liquid sintering process. These methods can utilize a shortened liquid sintering process while still producing articles having improved properties including corrosion resistance. Also described are articles formed by these methods.
Disclosed herein are colorants and methods of making and use thereof. For example, disclosed herein are colorant compositions comprising a hydroxyphenyl pyranoanthocyanin of Formula (I). Also disclosed herein are thermal degradation compounds derived via thermal degradation of any of the colorants disclosed herein. Also disclosed herein are thermal degradation compounds derived via thermal degradation of 10-catechyl-pyranocyanidin-3-O-β-glucoside. In some examples, the thermal degradation compound comprises 4-carboxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium. Also disclosed herein are compositions, beverages, food products, edible products, cosmetic products, and/or dye sensitized solar cells comprising any of the colorants and/or thermal degradation compounds disclosed herein. Also disclosed herein are methods of making any of the colorants and/or thermal degradation compounds disclosed herein.
A smoking machine adaptor device including a base configured to couple to a smoking machine, the base defining a central axis and a base cavity, a cap including a cap flange defining a cap aperture, and a cap actuator coupled to the base and configured to move the cap flange relative to the base along the central axis between a first position to a second position, and a resiliently deformable ferrule sized to be received within the base cavity and defining a ferrule aperture aligned axially with the cap aperture along the central axis. The ferrule aperture defines a. first ferrule area in a plane perpendicular to the central axis when the cap flange is in the first position, a. second, smaller ferrule area in the plane perpendicular to the central axis when the cap flange is in the second position.
Described herein are sensors for detecting an analyte of interest in a sample. These sensors can comprise a potentiometric sensor comprising a surface functionalized with a pH-sensitive aptamer switch that specifically binds the analyte of interest, wherein the pH-sensitive aptamer switch is operatively coupled to the potentiometric sensor such that binding of the analyte of interest by the pH-sensitive aptamer switch induces a measurable change in the potentiometric sensor; and an auxiliary electrode in proximity to the surface, wherein the electrode is configured to alter a pH of a microenvironment in contact with the surface, thereby reversibly shuttling the pH-sensitive aptamer switch between a first state wherein it specifically binds the analyte of interest and a second state wherein it does not specifically bind the analyte of interest.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
6.
DEVICE TO RESTRAIN OPENING OF AN OFF-THE-SHELF SURGICAL INSTRUMENT
A device for retaining a medical instrument includes a main body extending along a curved longitudinal axis. The main body defines a channel extending along the curved longitudinal axis. A first slot of the main body extends in a direction substantially perpendicular to the curved longitudinal axis. A clamp member is coupled to a hinge protrusion of the main body and movable between an open and a closed configuration wherein, in the closed configuration, the clamp member encloses a portion of the first slot. A mechanical stop is coupled to the channel of the main body and configured to be moved between (i) a stationary configuration wherein the mechanical stop is fixed at a first point in the channel, and (ii) an adjustable configuration wherein the mechanical stop is movable to a second point along the channel of the main body.
A61B 17/122 - Clamps ou pinces, p. ex. pour le cordon ombilical
A61B 17/10 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour poser ou retirer les clamps pour blessuresChargeurs de clamps pour blessures
A61B 17/128 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical pour appliquer ou enlever les clamps ou les pinces
7.
SUSTAINED PERFUSION DEVICE IN MODULAR MICROFLUIDIC DEVICES
A system may include a liquid hopper including a hopper wall defining an internal volume, an inlet coupled to the hopper wall, a funnel coupled to the hopper wall and defining an outlet in fluid communication with the inlet, a hydraulic resistor mount coupled to the hopper wall between the inlet and the outlet, and a hydraulic resistor coupled to the membrane mount. A system may include a microfluidic device comprising an extracellular matrix (ECM) derived hydrogel, and defining a lumen therethrough fluidly coupled to the outlet of the liquid hopper, wherein when liquid flows from the outlet and subsequently into the lumen of the microfluidic device, the liquid is permitted to perfuse at least one of: i) the lumen and ii) a wall of the microfluidic device.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
An example computer-implemented method for image reconstruction, includes: receiving k-space data from a magnetic resonance imaging (MRI) machine, the k-space data comprising a plurality of k-space readouts; sorting the k-space readouts into a set of bins comprising binned k-space data, each of the set of bins corresponding to a respective phase of a respiratory cycle; iteratively performing the steps of: (i) computing a soft participation weight for each k-space readout, where the soft participation weight reflects a posterior probability that each k-space readout belongs to each of the set of bins; and (ii) updating an image estimate by solving a weighted optimization problem; determining a convergence criterion is reached; and outputting a motion-resolved volumetric MRI image when the convergence criterion is reached.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Disclosed herein are devices and methods of making and use thereof. For example, disclosed herein are devices comprising a dielectric layer comprising a first dielectric material, a semiconductor layer comprising a semiconductor material, a first and second electrode, and one or more trenches within the dielectric layer, the trenches being at least partially filled with a second dielectric material that is different than the first dielectric material. The dielectric layer is deposited on the semiconductor layer; the dielectric layer has a top surface opposite the semiconductor layer; the semiconductor layer has a bottom surface opposite the dielectric layer; and the first and second electrodes are arranged such that the device is a lateral device or a vertical device. Parameters of the devices are selected to control the electric field distribution when a bias is applied between the first and second electrodes.
11.
METHODS OF DIAGNOSING, PROGNOSING, AND TREATING CANCERS OVEREXPRESSING miR-155
Disclosed herein are methods of diagnosing severity, aggressiveness, or prognosis of a solid cancer by determining if miR-155 is overexpressed. Also disclosed herein are methods of treating, preventing, decreasing, eliminating, and/or ameliorating a cancer by synthetic nucleic acids encoding administering inducible T-cell costimulatory ligand (ICOSL) and/or RELA, thereby upregulating ICOSL and MHC-I on cancerous cells to improve the efficacy of immune cell therapies and checkpoint inhibitors. Any of the disclosed methods can further be paired with administration of an miR-155 inhibitor (e.g., cobomarsen).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
An example system includes a controller including a plurality of independently addressable output channels, a set of independently addressable input channels, and a wireless transceiver; an animal-behavior testing device operably coupled to an input channel of the set of independently addressable input channels or an output channel of the set of independently addressable output channels; and a computing device in operable communication with the wireless transceiver of the controller.
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Methods of treating cancer in a subject in need thereof are provided. The methods include administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or derivative thereof. Compounds and compositions are also provided.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
15.
A LASER BEAM PROFILE MEASUREMENT TECHNIQUE FOR HIGH-ENERGY LASERS USED IN METAL MANUFACTURING PROCESSES
A system for measuring a laser beam profile of industrial high-power lasers. The setup incorporates UV fused silica windows for beam attenuation and a combination of reflective and absorptive neutral density filters to further reduce beam intensity. Achromatic doublet lenses refocus the attenuated beam, to create a magnified low-power replica suitable for high-resolution measurements. This configuration allows for continuous real-time monitoring of the laser caustic parameters and the laser beam profile along its optical axis.
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
Disclosed herein are systems and methods for ionizing compounds. In some implementations, the systems and methods include a first voltage and second voltage, applied in a continuous voltage sweep from a voltage of less than 2 kV to a voltage of greater than 4 kV.
B05B 5/00 - Pulvérisation électrostatiqueDispositifs de pulvérisation comportant des moyens pour charger électriquement le pulvérisatPulvérisation de liquides ou d'autres matériaux fluides par voies électriques
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
An operating table for a small animal may include a housing defining a depression sized to receive a small animal. An operating table for a small animal may include an adjustable nosecone including: a head support liner coupled to the housing and elevated relative to the depression, a delivery port for receiving medicated gas; and a vacuum port configured to couple to a vacuum source to remove excess medicated gas.
A61D 3/00 - Appareils pour soutenir ou ligoter les animaux à opérer
A61D 7/04 - Dispositifs pour anesthésier les animaux au moyen de gaz ou vapeursDispositifs pour inhalations
18.
NONINVASIVE SYSTEMS AND METHODS FOR QUANTIFYING NEURAL SYNCHRONY IN THE COCHLEAR NERVE AND CORRELATING THE QUANTIFIED NEURAL SYNCHRONY WITH TEMPORAL RESOLUTION ACUITY AND SPEECH PERCEPTION OUTCOMES MEASURED IN QUIET AND IN NOISE
Disclosed herein are of systems, methods, and computer-program products of determining a peripheral neural synchrony value based on eCAPS and correlating the peripheral neural synchrony value with temporal resolution acuity and speech perception outcomes measured in quiet and in noise in the patient.
A61B 5/388 - Études de la conduction nerveuse, p. ex. détection du potentiel d’action d’un nerf périphérique
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
19.
PREPARATION OF MATERIALS HAVING CONTROLLED MORPHOLOGIES USING SELF-REGULATING TECHNOLOGY
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
Exemplary systems and methods convert stranded natural gas (SNG) to liquid fuels. Broadly, exemplary systems and methods include a reforming stage, a heat integration stage, and a liquid fuel generation stage.
C10G 5/06 - Récupération de mélanges liquides d'hydrocarbures à partir de gaz, p. ex. gaz naturel par refroidissement ou compression
C10L 3/10 - Post-traitement de gaz naturel ou de gaz naturel de synthèse
C01B 3/38 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants avec des catalyseurs
21.
PARTICLES COMPRISING PROTEINS ENCAPSULATED IN A POROUS FRAMEWORK AND METHODS OF USING THEREOF
Disclosed are methods for producing matrix-encapsulated proteins, including matrix-encapsulated hemoglobin. Also provided are pharmaceutical compositions comprising a matrix-encapsulated hemoglobin, as well as methods of using thereof to treat hypoxia, cyanide poisoning, hydrogen sulfide poisoning, and/or azide poisoning.
Disclosed herein is a tagless bispecific two antibody (bsAb) biopharmaceutical with the hallmark ability to bind two separate targets. The two separate targets are T-cells and the proximal cancer cells to initiate an immune response. The disclosed bsAbs have extended half-lives with a focus on human serum albumin affibody (HSA)-fusions.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
An example device includes a first piezoelectric member; and a linear actuator coupled to a stopper member, where the linear actuator is configured to control a resonant frequency of the device by adjusting a gap between the first piezoelectric member and elastic stopper member. An example device includes a first piezoelectric member coupled to a slider, and a second piezoelectric member coupled to the slider, where the first piezoelectric member and second piezoelectric member are separated by a gap.
H02N 2/18 - Machines électriques en général utilisant l'effet piézo-électrique, l'électrostriction ou la magnétostriction fournissant une sortie électrique à partir d'une entrée mécanique, p. ex. générateurs
H10N 30/30 - Dispositifs piézo-électriques ou électrostrictifs à entrée mécanique et sortie électrique, p. ex. fonctionnant comme générateurs ou comme capteurs
Systems, Methods and Devices for Map-Based Object's Localization Deep Learning and Object's Motion Trajectories on Geospatial Maps Using Neural Network
An object of initial unknown position on a map may be determined by traversing through moving and turning to establish motion trajectory to reduce its spatial uncertainty to a single location that would fit only to a certain map trajectory. A artificial neural network model learns from object motion on different map topologies may establish the object's end-to-end positioning from embedding map topologies and object motion. The proposed method includes learning potential motion patterns from the map and perform trajectory classification in the map's edge-space. Two different trajectory representations, namely angle representation and augmented angle representation (incorporates distance traversed) are considered and both a Graph Neural Network and an RNN are trained from the map for each representation to compare their performances. The results from the actual visual-inertial odometry have shown that the proposed approach is able to learn the map and localize the object based on its motion trajectories.
G01C 21/30 - Mise en coïncidence avec des cartes ou des contours
G01C 21/16 - NavigationInstruments de navigation non prévus dans les groupes en utilisant des mesures de la vitesse ou de l'accélération exécutées à bord de l'objet navigantNavigation à l'estime en intégrant l'accélération ou la vitesse, c.-à-d. navigation par inertie
G06N 3/0442 - Réseaux récurrents, p. ex. réseaux de Hopfield caractérisés par la présence de mémoire ou de portes, p. ex. mémoire longue à court terme [LSTM] ou unités récurrentes à porte [GRU]
G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
25.
MAGNESIUM ALLOYS AND METHODS OF MAKING AND USE THEREOF
Disclosed herein are magnesium alloys and methods of making and use thereof. The magnesium alloys comprise: from 1 to 1.5 wt. % Zn, from 1 to 1.4 wt. % Al, from 0.2 to 0.7 wt. % Ca, from 0.2 to 0.4 wt. % Ce, from 0.1 to 0.8 wt. % Mn, and the balance comprising Mg.
C22C 23/02 - Alliages à base de magnésium avec l'aluminium comme second constituant majeur
C22F 1/06 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid du magnésium ou de ses alliages
26.
RANGE EXTENSION WITH OPTIMAL TRACTION CONTROL FOR MULTI E-AXLE BASED ELECTRIFIED VEHICLES
Systems and methods for range extension with optimal traction control for multi e-axle based electrified vehicles are disclosed. The systems and methods optimize the operation of electric vehicles with multiple e-axles by generating optimal torque profiles based on look-ahead information about road conditions and optimally distributing torque between e-axles to minimize energy losses and extend driving range. The optimal traction control system operates in three main steps: first, generating an optimal torque profile based on look-ahead information about road grade and speed limits; and second, optimally allocating the requested torque between multiple e-axles to minimize energy losses. Third, dynamic drive control for electric machine to track optimal torque with minimized current. The optimal torque profile follows the trend of the road grade, providing more torque on uphill sections and less torque or even negative torque on downhill sections.
B60L 15/20 - Procédés, circuits ou dispositifs pour commander la propulsion des véhicules à traction électrique, p. ex. commande de la vitesse des moteurs de traction en vue de réaliser des performances désiréesAdaptation sur les véhicules à traction électrique de l'installation de commande à distance à partir d'un endroit fixe, de différents endroits du véhicule ou de différents véhicules d'un même train pour la commande du véhicule ou de son moteur en vue de réaliser des performances désirées, p. ex. vitesse, couple, variation programmée de la vitesse
B60L 7/10 - Freinage dynamo-électrique par récupération
B60L 50/60 - Propulsion électrique par source d'énergie intérieure au véhicule utilisant de la puissance de propulsion fournie par des batteries ou des piles à combustible utilisant de l'énergie fournie par des batteries
B60L 58/12 - Procédés ou agencements de circuits pour surveiller ou commander des batteries ou des piles à combustible, spécialement adaptés pour des véhicules électriques pour la surveillance et la commande des batteries en fonction de l'état de charge [SoC]
Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
C07C 279/12 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des atomes d'azote ne faisant pas partie de groupes nitro ou nitroso
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 5/068 - Dipeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
28.
SYSTEMS AND METHODS FOR MECHANICAL DISPLACEMENT OF AN ESOPHAGUS
An example assembly for use with a vacuum system and an esophageal positioning device esophageal positioning device includes an introducer, in which the esophageal positioning device includes a handle, a first segment, a second segment and an articulation driving mechanism. The first segment being coupled to the handle. The second segment being pivotally connected to the first segment. The articulation driving mechanism being configured to pivot the second segment about the first segment upon articulation.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61B 1/015 - Commande de l'alimentation en fluide ou de l'évacuation de fluide
A61B 1/273 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'appareil digestif supérieur, p. ex. œsophagoscopes, gastroscopes
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/01 - Mesure de la température de parties du corps
A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
Various implementations include an automated endotracheal intubation device, including: a flexible tube sized to be advanced within a patient's airway; a base system; and a deployment arm having a proximal end coupled to the base system and a distal end spaced apart from the proximal end, the deployment arm including: at least one arm segment coupled to and extending from the base system, the at least one arm segment defining a channel within which the flexible tube is disposed; and an end effector coupled to the distal end of the deployment arm, the end effector including one or more twisted and coiled polymer (TCP) tendons configured to controllably expand and contract upon application of heat.
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
30.
LPA RECEPTOR ANTAGONIST-DERIVED LIPID COMPOUNDS AND USES THEREOF
C07C 219/22 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant non saturé et contenant des cycles aromatiques à six chaînons
A method for beam-training a phased array antenna, including: transmitting, from the phased array antenna, one or more probing beams; receiving, at one or more receivers, the one or more probing beams; determining, based on the received one or more probing beams, a correlation between each transmitted preamble signal and each received preamble signal; determining, based on the correlation between each transmitted preamble signal and each received preamble signal, one or more signal paths; determining a channel impulse response (CIR) value for each of the one or more signal paths; determining, based on the CIR value for each of the one or more signal paths, a direction corresponding to each of the one or more signal paths; and generating, from the phased array antenna, a subsequent beam based on a complex gain corresponding to a signal path of the one or more signal paths.
H04B 7/06 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
H04W 16/28 - Structures des cellules utilisant l'orientation du faisceau
An example method includes: receiving an uplink channel by an RF front end module; partitioning the uplink channel into a plurality of sub-channels by a neural network channel divider, wherein the plurality of sub-channels correspond to a plurality of non-overlapping distance ranges; generating, a plurality of coarse distance estimates by a neural network distance estimator, wherein the plurality of coarse distance estimates comprise a distance estimate for each of the plurality of sub-channels; generating a plurality of fine-tuned distance estimates by optimizing the plurality of coarse distance estimates; and determining, from the plurality of fine-tuned distance estimates, a downlink channel prediction, wherein the downlink channel prediction predicts a downlink channel based on the uplink channel.
H04W 28/088 - Équilibrage ou répartition des charges entre les entités centrales
H04W 72/21 - Canaux de commande ou signalisation pour la gestion des ressources dans le sens ascendant de la liaison sans fil, c.-à-d. en direction du réseau
H04W 72/23 - Canaux de commande ou signalisation pour la gestion des ressources dans le sens descendant de la liaison sans fil, c.-à-d. en direction du terminal
B32B 37/12 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par l'usage d'adhésifs
B32B 7/08 - Liaison entre couches par des moyens mécaniques
B32B 7/12 - Liaison entre couches utilisant des adhésifs interposés ou des matériaux interposés ayant des propriétés adhésives
B32B 15/10 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de bois
B32B 38/00 - Opérations auxiliaires liées aux procédés de stratification
34.
COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
35.
SYSTEMS AND METHODS OF CALIBRATING A PHASED ARRAY ANTENNA
A method including: equipping each antenna element in a mmWave antenna with 2 -bit phase shift registers; for each antenna element, cycling through predetermined phase shifts to receive signals associated with each of the predetermined phase shifts; processing RSS values of the received signals to determine a relative gain of the nth element in comparison to the 1st element; and repeating the above process for other elements, to determine a relative gain of each element with respect to the 1st element.
H01Q 3/36 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la phase relative ou l’amplitude relative et l’énergie d’excitation entre plusieurs éléments rayonnants actifsDispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante faisant varier la phase par des moyens électriques avec des déphaseurs variables
H01Q 21/22 - Réseaux d'unités d'antennes, de même polarisation, excitées individuellement et espacées entre elles les unités d'antennes du réseau étant excitées d'une façon non uniforme en amplitude ou en phase, p. ex. réseau à prises ou réseau bidirectionnel
A drainage apparatus adapted to extend over a window for drainage. The drainage apparatus is comprised of at least one piece of sheet metal, which defines a first end portion and a second end portion that are, respectively, adapted to extend over a face of a window for drainage. Each end portion defines at least one elongated opening configured for receiving a fastener adapted to secure the drainage apparatus, respectively, over different sizes of windows for drainage. A middle portion is defined between the first end portion and the second end portion, wherein the middle portion defines a plurality of drainage openings that, respectively, have a dimension of at least two inches to perform the screening function.
An example computer implemented method includes receiving a plurality of optimization variables; receiving a cost function representing a vehicle system, where the cost function includes a plurality of weights assigned to the plurality of optimization variables; decomposing the cost function into a plurality of problems; and generating a solution to the cost function by solving the plurality of problems. An example system includes a vehicle powertrain and a computing device configured to receive a plurality of optimization variables; receive a cost function representing a vehicle system, where the cost function comprises a plurality of weights assigned to the plurality of optimization variables; decompose the cost function into a plurality of control problems; generate a solution to the cost function by solving the plurality of control problems; and control the vehicle powertrain based on the solution to the cost function.
B60W 20/00 - Systèmes de commande spécialement adaptés aux véhicules hybrides
B60W 10/06 - Commande conjuguée de sous-ensembles de véhicule, de fonction ou de type différents comprenant la commande des ensembles de propulsion comprenant la commande des moteurs à combustion
A patient transfer device includes a first roller and a second roller each extending from the first end to a second end of the patient transfer device in a longitudinal direction. The first and second rollers are rotatably coupled to a first end bar on the first end of the device. The second roller is spaced apart from the first roller in a lateral direction perpendicular to the longitudinal direction. The device includes a belt extending between and supported by each of the first roller and the second roller. The belt is configured to advance in a first rotational direction around the first roller and the second roller. A motor is coupled to the first roller and configured to rotate the first roller to advance the belt. The device includes a controller in electrical communication with the motor, the controller configured to selectively activate the motor.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
40.
SYSTEM, METHOD, AND COMPUTER-PROGRAM PRODUCT FOR ESTABLISHING VIRTUAL REALITY (VR) ENVIRONMENTS FOR HUMAN RELIABILITY ASSESSMENT FOR PHYSICAL SECURITY
The disclosed systems, methods, and computer program products are used to develop a virtual reality high-fidelity simulator that leverages existing tools and couples physics-based simulation for optimal rendering of the environmental conditions surrounding the operators, attackers, and defenders. It, therefore, permits meaningful data collection on human errors and performance-shaping factors (via, for instance, biometric data). The collected data facilitates an understanding of human activities that can occur in a situation of attack and defense and of the contexts that may be prevalent, as well as possible groupings in representative sub-classes, and the modifications that should be brought to human reliability models for such a set of conditions.
G05B 17/00 - Systèmes impliquant l'usage de modèles ou de simulateurs desdits systèmes
G06F 3/04815 - Interaction s’effectuant dans un environnement basé sur des métaphores ou des objets avec un affichage tridimensionnel, p. ex. modification du point de vue de l’utilisateur par rapport à l’environnement ou l’objet
G06F 9/455 - ÉmulationInterprétationSimulation de logiciel, p. ex. virtualisation ou émulation des moteurs d’exécution d’applications ou de systèmes d’exploitation
G06F 30/20 - Optimisation, vérification ou simulation de l’objet conçu
G06F 30/3308 - Vérification de la conception, p. ex. simulation fonctionnelle ou vérification du modèle par simulation
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
G06Q 10/0631 - Planification, affectation, distribution ou ordonnancement de ressources d’entreprises ou d’organisations
G06Q 10/0639 - Analyse des performances des employésAnalyse des performances des opérations d’une entreprise ou d’une organisation
G06Q 90/00 - Systèmes ou méthodes spécialement adaptés à des fins administratives, commerciales, financières, de gestion ou de surveillance, n'impliquant pas de traitement significatif de données
G06T 19/00 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie
An endotracheal intubation system includes an external frame including a carriage controllably movable via at least one external actuator. An internal frame coupled to the carriage includes a plurality of interlocked segments along a longitudinal axis, each segment defining a plurality of openings. A plurality of tension cables extends longitudinally from the carriage to a free end of the internal frame through the plurality of openings of the interlocked segments. At least one internal actuator is coupled to and configured to adjust the plurality of tension cables to adjust the curvature of the plurality of interlocked segments. The internal frame extends through a channel of a flexible intubation tube that is configured to conform to a shape of the internal frame. A controller is in communication with the internal and external actuators. The controller is configured to move the internal frame to navigate an airway of a patient.
A portable anesthesia monitoring device includes a housing and a screen. A first syringe channel is defined on the back side of the housing to retain a syringe therein. A flange retainer and a plunger retainer are adjacent to the first syringe channel and moveable relative to each other. A linear actuator is coupled between the flange retainer and the plunger retainer to change an internal volume of the first syringe. At least one sensor is configured to communicate patient data to the device. A controller is in electrical communication with each of the screen, the linear actuator, and the at least one sensor, the controller configured to (i) continuously display patient data from the at least one sensor on the screen and (ii) initiate movement of the plunger retainer to expel a fluid from the first syringe at a controlled flow rate.
G01F 1/00 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu
G01F 23/00 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p. ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme
43.
METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE
Disclosed herein are 4,6-substituted-2-(3'-[1,1'-biphenyl]-4-yl)quinoline analogs and pharmaceutically acceptable salts thereof that are inhibitors of dihydroorotate dehydrogenase (DHODH) with properties, including stability and bioavailability as disclosed herein. Also disclosed herein are methods of making the analogs and salts thereof. The disclosed analogs and salts thereof can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation.
C07D 215/52 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène liés en position 4 avec des radicaux aryle liés en position 2
A colon evaluation system includes a patency capsule configured to be swallowed by a patient and a colon evaluation device configured to be removably coupled to the patient. The patency capsule having a tracking device supported therein. The colon evaluation device includes a plurality of detector devices configured to receive a signal from the tracking device to determine the position of the patency capsule within the patient's body in real-time, and a computing device configured to be communication with the detector devices. The computing device configured to receive information from the detector devices related to the position of the tracking device in the patency capsule in real-time.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
A container can be used for the sanitation of food products, wherein the container comprises a UV light which can irradiate the food. This allows for food to last longer, as the UV light can reduce or eliminate microbes on the food. This also increases the safety of the food for consumption. The UV light can be activated when low light conditions are sensed, such as in a refrigerator with the door shut.
A component manufacturing device called Auto-Fab (100) is disclosed. Each Auto-Fab system is a self-contained device including a housing (150), tools (120), robotics (110), sensors (113), and computing functionality (115) that is configured to manufacture a variety of components (160) using various materials available at a location of the Auto-Fab. The Auto-Fab, using the robotics and tools, may be programed to autonomously perform a variety of manufacturing techniques including, but not limited to, deformation, casting, machining, and welding The manufacturing processes used by the Auto-Fab for a particular component may be designed using an iterative feedback method (200; 300) where the manufacturing processes are continuously tweaked and tuned based on a comparison of a manufactured component with predicted attributes.
B23P 21/00 - Machines pour l'assemblage de nombreuses pièces différentes destinées à composer des ensembles, avec ou sans usinage de ces pièces avant ou après leur assemblage, p. ex. à commande programmée
Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
48.
COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS
Described are peptides including a membrane translocation domain having one or more cell penetrating peptide motifs, and a cargo moiety linked to the membrane translocation domain, wherein the cargo moiety includes a plant bioactive moiety. The at least one cell penetrating peptide motif is from 3 to 10 amino acid residues in length and has at least three arginine and/or lysine residues; or the at least one cell penetrating peptide motif is from 3 to 10 amino acid residues in length and has at least two arginine and/or lysine residues and at least one other cell penetrating peptide motif is from 2 to 8 amino acid residues in length and has at least two hydrophobic residues. Also described are methods of delivering a cargo moiety into a plant cell comprising contacting the plant cell with the peptide as disclosed herein.
INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (République de Corée)
Inventeur(s)
Park, Sungjin
Abrégé
Disclosed herein are compositions, devices, and methods of making and use thereof. For example, disclosed herein are composite materials comprising a plurality of particles comprising silicon (Si) (e.g., a plurality of silicon particles); and a graphene; wherein the plurality of particles comprising silicon are dispersed substantially uniformly on the graphene. Also disclosed herein are electrodes and batteries comprising any of the composite materials disclosed herein.
Methods of treating cancer in a patient in need thereof are described herein. In some embodiments, the method comprises regulating the expression of at least one gene in a CD8+T cell.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A device for migraine treatment through myofascial release is disclosed. The device includes a pin chassis and a motor to move the pin chassis in a first direction and a second direction. The device includes a pin coupled to the pin chassis with an end effector disposed at the distal end thereof. The device includes an actuator configured to selectively facilitate movement of the end effector between an extended and a retracted configuration. The device includes a controller in electrical communication with each of the motor and the actuator, the controller configured to (i) activate the motor to move the pin chassis in the first direction or the second direction, and (ii) activate the actuator to extend or retract the end effector.
A61H 39/04 - Dispositifs pour exercer des pressions auxdits endroits, p. ex. shiatsu
A61H 23/04 - Massage par percussion ou vibration, p. ex. en utilisant une vibration ultrasoniqueMassage par succion-vibrationMassage avec des membranes mobiles à entraînement hydraulique ou pneumatique
The present disclosure provides a method of inducing terminal exhaustion in a population of CAR-T cells, as well as populations of terminally exhausted CAR-T cells prepared by these methods. Also provided are methods of using these methods and these populations of terminally exhausted CAR-T cells for screening for agents that can reverse or prevent terminal dysfunction in CAR T cells.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are compounds comprising a phosphonoalamide of Formula (I) and/or Formula (II). In some examples, the compound is a salt, such as a salt form of Formula (I) and/or Formula (II) with a counterion. Also disclosed herein are compositions comprising any of the compounds disclosed herein, such as pharmaceutical and/or agricultural compositions. Also disclosed herein are methods of use of any of the compounds and/or compositions disclosed herein, for example to control an undesirable population, such as a microbe (e.g., bacteria). Also disclosed herein are methods of reducing the activity of bacteria; reducing bacterial population; killing bacteria; treating, preventing, inhibiting, and/or ameliorating a disease or disorder in a plant or a subject in need thereof, such as a microbial (e.g., bacterial) infection; or a combination thereof using any of the compounds and/or compositions disclosed herein.
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A01N 57/20 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore comportant des liaisons phosphore-carbone contenant des radicaux acycliques ou cycloaliphatiques
Bluetooth Address Tracking (BAT) is an allowlist-based side channel attack to track Bluetooth devices, by either passively sniffing the Bluetooth packets, or actively replaying the sniffed ones. Securing addresses of Bluetooth Low Energy (BLE) is described, which uses an interval unpredictable, central and peripheral synchronized random media access control (MAC) address generation scheme to defend against passive BAT attacks, and uses a current timestamp to derive random MAC addresses to defeat active BAT attacks, such that attackers can no longer be able to replay them.
H04W 12/122 - Contre-mesures pour parer aux attaquesProtection contre les dispositifs malveillants
H04W 4/80 - Services utilisant la communication de courte portée, p. ex. la communication en champ proche, l'identification par radiofréquence ou la communication à faible consommation d’énergie
Various implementations include a sweeping jet device with multidirectional output. The device includes an interaction chamber defined by a chamber wall. The chamber wall defines first and second inlet ports and first and second outlet ports. First and second fluid supply inlets are configured to introduce first and second inlet fluid streams through the first and second inlet ports, respectively, and into the interaction chamber. First and second outlet nozzles are configured to discharge first and second outlet fluid streams from the interaction chamber through the first and second outlet ports and the first and second outlet nozzles, respectively. The first and second inlet fluid streams collide within the interaction chamber causing the first and second outlet fluid streams to sweep as the first and second outlet fluid streams are discharged from the first and second outlet nozzles, respectively.
B05B 1/08 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage agencés pour produire un jet, un pulvérisat ou tout autre écoulement de forme ou de nature particulière, p. ex. sous forme de gouttes individuelles de nature pulsatoire, p. ex. débitant un liquide en quantités successives séparées
56.
METHODS AND COMPOSITIONS FOR FAST-CHARGING ANODES FOR LITHIUM ION BATTERIES
Described herein is a solid electric conductor and methods of making and using the solid electric conductor. The solid electric conductor can include two discrete populations of particles intermixed. A first population of particles can include an ionically conducting solid-electrolyte, and a second population of particles can include an electrode active material. The compositions and methods described allow to achieve high specific energy, good cycle/calendar life, and low cobalt (Co) loading to reduce the cost of battery cells.
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
57.
METHODS OF TREATMENT USING TGFb-RECEPTOR 1 INHIBITION AND LTBR AGONISM
Methods of treating a patient in need thereof are described herein. In some embodiments, the method comprises disposing a TGFb-receptor 1 inhibitor within a biological compartment of the patient, and disposing a lymphotoxin beta receptor (LTBR) agonist within the biological compartment of the patient. In some instances, the patient has cancer. In some cases, the cancer is pancreatic cancer, or more specifically pancreatic ductal adenocarcinoma. In tertiary lymphoid structures (TLS)-resistant tumors, the disposing of the TGFb-receptor 1 inhibitor within the biological compartment of the patient results in a reprogramming of fibroblast phenotype and overcomes resistance to generation of TLS in tumors of the patient.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
58.
SYSTEM AND METHOD FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT USING COGNITIVE TEST RESULTS WITH ITS BEHAVIORAL METADATA
An exemplary system and method are disclosed that is configured to detect cognitive impairment (e.g., early cognitive impairment) or assess cognitive function by analyzing, via machine learning and artificial intelligence analysis, behavioral metadata collected from a smart app during the course when a subject is using a cognitive test instrument for cognitive tests that incorporate motor activity (e.g., drawing or writing). The machine learning and artificial intelligence analysis can execute features associated with the test taker's metadata (e.g., time spent on task or questions, changing answers, referring back to the previous question), drawing qualities (e.g., line straightness, completeness), among others.
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
59.
METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS
Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/529 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime formant une partie de systèmes cycliques pontés
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
Systems, apparatuses, methods, and computer program products are disclosed for visualizing institutional engagement of a population. An example method includes receiving engagement data from a plurality of data sources. The example method also includes determining, in near-real-time and based on the engagement data, an engagement phase for each individual within the population. The example method also includes rendering a visual representation of engagement phase composition based on the determined engagement phase for each individual within the population.
Disclosed herein are systems, methods and computer-program products to create synthetic immunohistochemistry (IHC) stained digital slides or virtual tissue sections generated using artificial neural networks (ANNs). In some implementations, the created digital slides or a virtual tissue sections can be used as a ground truth to evaluate a method of analyzing IHC stained tissues.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A clinical decision support system and method for patients with pulmonary arterial hypertension is disclosed herein. The system may comprise a processor to process instructions to execute one or more pulmonary arterial hypertension risk algorithms configured to generate a risk score value associated with a patient surviving within a given time period. The system may comprise a means for input and output, wherein input variable data may be received and a set of risk score values may be displayed. A method for operating the clinical decision support system is also disclosed.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 70/20 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pratiques ou des directives
63.
PHOSPHONOPEPTIDES AND METHODS OF MAKING AND USE THEREOF
Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are compound defined by Formula I or a derivative or salt thereof. In some examples, the compound comprises AmPn-Arg-Val-DMA, AmPn-NeSalinispora Salinispora isolate or a derivative or salt thereof.
A01N 57/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore comportant des liaisons phosphore-carbone
Membranes, methods of making the membranes, and methods of using the membranes are described herein. The membrane can include a support layer, and a selective polymer layer disposed on the support layer. The selective polymer layer can include a selective polymer matrix that comprises a mobile carrier comprising a sterically hindered amine or a salt thereof. The selective polymer matrix can further comprise, for example, a hydrophilic polymer, a cross-linking agent, an amine-containing polymer, or a combination thereof. The membranes can be used to separate hydrogen sulfide from carbon dioxide. Also provided are methods of purifying syngas using the membranes described herein.
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
B01D 69/10 - Membranes sur supportSupports pour membranes
In an aspect, the present disclosure relates to a method. In one implementation, the method includes providing a material in an air-tight chamber defining an inlet and an outlet; supplying a direct current voltage to an electrode proximate to the material to generate ions in the air-tight chamber; introducing a carrier gas to the air-tight chamber at the inlet; and collecting the carrier gas and the ions at the outlet.
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
G01N 27/623 - Spectrométrie de mobilité ionique combinée à la spectrométrie de masse
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
66.
Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2
Methods and materials for intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided. Use of the methods and materials is contemplated, for example, for the treatment of Rett syndrome.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
67.
COMPOSITIONS, KITS, AND METHODS FOR THE PRESERVATION OF BLOOD PRODUCTS
Provided herein are compositions and methods for reducing the concentration of hemolytic biproducts in a blood product stored ex vivo. These compositions and methods can also be used to prolong the shelf life of blood products ex vivo. Also provided herein are sterile blood bags that contain the compositions described herein.
Methods and compositions for retinal gene therapy are described herein. In one aspect, a method of treating a patient in need thereof is described. In some embodiments, the method comprises performing a vitrectomy on the eye of the patient, and delivering a payload, such as a gene therapy vector, to the retina of the eye of the patient. In some instances, the method further comprises removing the inner limiting membrane (ILM) of the eye of the patient before delivering the payload to the retina of the eye of the patient. In one aspect, compositions for retinal gene therapy are described. In such embodiments, a composition comprises a payload and an adjuvant.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A device for retaining a medical instrument includes a main body extending along a curved longitudinal axis. The main body defines a channel extending along the curved longitudinal axis. A first slot of the main body extends in a direction substantially perpendicular to the curved longitudinal axis. A clamp member is coupled to a hinge protrusion of the main body and movable between an open and a closed configuration wherein, in the closed configuration, the clamp member encloses a portion of the first slot. A mechanical stop is coupled to the channel of the main body and configured to be moved between (i) a stationary configuration wherein the mechanical stop is fixed at a first point in the channel, and (ii) an adjustable configuration wherein the mechanical stop is movable to a second point along the channel of the main body.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
Devices for high throughput cell electroporation include a trapping component that at least partially defines an upper boundary of a microfluidic chamber. A cell trap array is patterned on the underside of the trapping component, and a channeling component is positioned beneath the trapping component. The channeling component includes a vertically oriented nanochannel array. The trapping component and the channeling component are positioned such that a given nanochannels is positioned beneath a cell trap. During use, fluid flow holds trapped cells in secure contact with the nanochannels beneath the cell trap. The device further includes upper and lower electrode layers for generating an electric field to electroporate trapped cells via the nanochannel array. A reservoir positioned beneath the channeling component can be filled transfection reagent solution. During electroporation, the transfection reagent solution travels through the nanochannel array during to transfect the trapped cells.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p. ex. par magnétisme, par des ondes sonores
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
71.
METHODS, DEVICES, AND MANUFACTURE OF THE DEVICES FOR MUSCULOSKELETAL RECONSTRUCTIVE SURGERY
A device used in conjunction with fixation hardware to provide a two-stage process to address the competing needs of immobilization and re-establishment of normal stress-strain trajectories in grafted bone. A method of determining a patient-specific stress/strain pattern that utilizes a model based on 3D CT data of the relevant structures and cross-sectional data of the three major chewing muscles. The forces on each of the chewing muscles are determined based on the model using predetermined bite forces such that a stiffness of cortical bone in the patient's mandible is determined. Based on the stiffness data, suitable implantation hardware can be designed for the patient by adjusting external topological and internal porous geometries that reduce the stiffness of biocompatible metals to thereby restore normal bite forces of the patient. A method of 3D printing nitinol to create a patient-specific device to facilitate the establishment of a normal stress-strain trajectory in grafted bone.
2222). Certain embodiments of the instant disclosure include 3-reactor chemical looping systems that utilize biomass as a carbonaceous fuel to generate hydrogen. Certain embodiments on the instant disclosure may utilize nitrogen from depleted air or oxygen-free air from a combustor reactor. Generated nitrogen and hydrogen in an adjustable ratio may be sent to the Haber Bosch process for the formation of ammonia.
C01B 3/02 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène
C01B 3/12 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés inorganiques comportant un hydrogène lié électropositivement, p. ex. de l'eau, des acides, des bases, de l'ammoniac, avec des agents réducteurs inorganiques par réaction de la vapeur d'eau avec l'oxyde de carbone
C01B 3/50 - Séparation de l'hydrogène ou des gaz contenant de l'hydrogène à partir de mélanges gazeux, p. ex. purification
73.
SYSTEMS AND METHODS FOR SINGLE MOLECULE LOCALIZATION MICROSCOPY (SMLM)
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (RFCUNY) REPRESENTING HUNTER COLLEGE (USA)
Inventeur(s)
Soltisz, Andrew
Veeraraghavan, Rengasayee
Craigmile, Peter
Abrégé
Provided herein are methods for analysis of single molecule localization microscopy (SMLM) data comprising a plurality of input data points in the form of molecular coordinates. These methods can identify clustering within input data points at all spatial scales within the input data set. These methods can comprise (i) grouping the plurality of input data points into clusters; (ii) discretizing the clusters into a discretized array; and (iii) measuring a spatial relationship between two species of localizations captured by the discretized array.
C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (RFCUNY) REPRESENTING HUNTER COLLEGE (USA)
Inventeur(s)
Soltisz, Andrew
Veeraraghavan, Rengasayee
Craigmile, Peter
Abrégé
Provided herein are methods for analysis of a data set comprising a plurality of input data points in the form of numbers or multidimensional coordinates. These methods can comprise: (a) processing the plurality of input data points to define a study area; (b) computing a tessellation cell for each of the plurality of input data points; (c) removing any tessellation cells that are unbounded or lie outside of the study area; (d) computing an instantaneous spatial density at each of the plurality of input data points using the tessellation cell; (e) identifying clustered data points as those whose instantaneous spatial density exceeds an analytically defined density threshold; and (f) grouping clustered data points into ensemble point clusters (clustered points with adjacent tessellation cells.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Disclosed are methods for preparing non-filamentous scaffolds (e.g., sheets) for cell or tissue culture. These methods can comprise providing at least a first printing composition (e.g., a bioink) and a second printing composition (e.g., a bioink or a fugitive ink); chaotic printing the first printing composition and the second printing composition to generate a microstructured precursor comprising a plurality of lamellar structures formed from the first printing composition and the second printing composition; extruding the microstructured precursor through a nozzle (e.g., a fan-shaped nozzle, a curved fan-shaped nozzle, or an annular nozzle) to produce a non-filamentous microstructured precursor; and curing the non-filamentous microstructured precursor to provide the non-filamentous scaffold for cell or tissue culture.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY (Mexique)
Inventeur(s)
Dean, David
Hooper, Ryan
Trujillo De Santiago, Grissel
Alvarez, Mario Moisés
Rodriguez, Ciro
Abrégé
Provided herein are methods for preparing perfusable scaffolds for cell culture. These methods can comprise providing a bioink composition and a fugitive ink composition; chaotic printing the bioink composition and the fugitive ink composition to generate a microstructured precursor comprising a plurality of lamellar structures formed from the bioink composition; curing the bioink composition to form a cured scaffold precursor; and removing the fugitive ink from the cured scaffold precursor, thereby forming the perfusable scaffold. In some embodiments, the fugitive ink comprises hydroxyethyl cellulose (HEC). In some embodiments, the the bioink composition and the fugitive ink composition are chaotically printed into a housing comprising a fluid inlet, a fluid outlet, and a path for fluid flow from the fluid inlet to the to generate a microstructured precursor occupying the path for fluid flow. Also provided are scaffolds prepared by these methods as well as modular bioreactors incorporating these scaffolds.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
80.
A MULTI-ADAPTABLE MELT ELECTROWRITING SYSTEM AND METHOD OF USING THE SAME
A melt electrowriting (MEW) system includes an MEW device configured to print a material on a collector. The MEW device includes a print head configured to melt and extrude the material out from an extruder. The extruder is exchangeable depending on a surface profile of the collector. The MEW device includes a positioning system configured to coordinate movements of the collector relative to the print head. The MEW system is configured to print the material with at least four mechanical degrees of freedom and up to six mechanical degrees of freedom.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
Disclosed herein is a novel set of cellular markers which can be used to rapidly analyze blood samples taken at early timepoints from patients treated with commercial CAR- T to predict risk of CAR-T failure in the long term. Subjects with predicted CAR-T failure can be treated with alternative therapies without waiting for a poor clinical outcome.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
82.
METHOD FOR PRODUCING THERAPEUTIC EXOSOMES FROM NANOELECTROPORATION AND OTHER NON-ENDOCYTIC CELL TRANSFECTION
Therapeutic extracellular vesicles (EVs) containing high copies of functional nucleic acids and other biomolecules are produced in large quantities by laying donor cells on a surface of a chip, adding various plasmids, other transfection vectors and their combinations to a buffer on the chip, applying a pulsulatic electric field across the cells laid on top of the chip surface and plasmids/vectors buffer solution below the chip surface, and collecting the EVs secreted by the transfected cells. The chip surface has a three-dimensional (3D) nanochannel electroporation (NEP) biochip formed on it, capable of handling large quantities of the donor cells. The buffer is adapted for receiving plasmids and other transfection vectors.
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p. ex. par magnétisme, par des ondes sonores
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
83.
DEVICE FOR ENSURING ACCURATE AND PRECISE PLACEMENT OF A MEDICAL SENSOR ON A PATIENT'S CHEST
A device for determining a precise placement of a medical sensor on a patient's chest is provided, the device comprising: a vertical portion including a sternal notice index portion for alignment with the patient's sternal notch, wherein the sternal notch index portion extends along a portion of the patient's sternum, wherein the vertical portion includes vertical patient size indices; and an arm extending from the vertical portion across the patient's midclavicular line, wherein the arm is oriented at a right angle to the vertical portion, wherein the arm includes horizontal patient size indices.
Described are cyclic peptides and compositions comprising such cyclic peptides. The cyclic peptides have a disulfide bond. Methods of making and using the cyclic peptides to deliver cargo moieties into cells are also described.
A protein purification system and methods of using the system, including using modified split inteins, shows unexpected cleavage rate results. In particular, this split intein comprises an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest. Through the self-cleaving mechanism of the intein, the protein of interest can be purified.
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
C07K 17/08 - Peptides immobilisés sur, ou dans, un support organique le support étant un polymère synthétique
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C12P 21/00 - Préparation de peptides ou de protéines
86.
METHODS OF FABRICATING SUPPORT LAYERS USING A COSOLVENT AND PORE FORMER
Described herein are methods of fabricating a nanoporous polymer membranes. These methods can comprise forming a film of a casting solution comprising a gas permeable polymer, a solvent, a co-solvent, and a porogen; contacting the film with humid air to induce phase separation in the film; and contacting the film with an aqueous solution to induce phase separation in the film.
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
22-philic ether, a graphene oxide, carbon nanotubes, or a combination thereof, dispersed within the polymer matrix. The membranes can be used to separate carbon dioxide from other gases, such as hydrogen and/or nitrogen. Also provided are methods of separating gas streams using the membranes described herein.
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
B01D 69/10 - Membranes sur supportSupports pour membranes
88.
POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF
Described herein is a continuous, roll-to-roll process for preparing a composite membrane. This process can comprise unrolling a porous polymer support layer from an input roll; forming a film of a casting solution on a porous polymer support layer, wherein the casting solution comprises a fixed carrier and a solvent; curing the film to form the composite membrane comprising a selective polymer layer disposed on the porous polymer support layer; and rewinding the composite membrane on a rewind roll while maintaining the composite membrane and the rewind roll at a relative humidity of less than 60% during rewinding.
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
Frequency stabilization is provided in a microelectromechanical systems (MEMS) oscillator via tunable internal resonance (IR). A device comprises a MEMS resonator comprising a stepped-beam structure that is a thin-layer structure. The resonator may be configured to implement IR. The stepped-beam structure may be configured to provide flexibility to adjust modal frequencies into a n:m ratio, wherein n and m are integers. The thin-layer structure provides frequency tunability by controlling the mid-plane stretching effect with an applied DC bias. The thin-layer structure compensates for a frequency mismatch from a n:m ratio due to a fabrication error. The MEMS resonator may be an oscillator.
H03H 3/007 - Appareils ou procédés spécialement adaptés à la fabrication de réseaux d'impédance, de circuits résonnants, de résonateurs pour la fabrication de résonateurs ou de réseaux électromécaniques
H03H 9/02 - Réseaux comprenant des éléments électromécaniques ou électro-acoustiquesRésonateurs électromécaniques Détails
H03H 9/24 - Détails de réalisation de résonateurs en matériau qui n'est ni piézo-électrique, ni électrostrictif, ni magnétostrictif
90.
THIN-FILM COMPOSITE MEMBRANE FORMATION WITH POLYGUANIDINE
Described herein are methods of fabricating a composite polymer membrane. These methods can comprise forming a film of a casting solution on a porous polymer support layer; and curing the film to form a selective polymer layer disposed on the porous polymer support layer. The casting solution can comprise a mobile carrier, a fixed carrier, and a solvent. The casting solution can exhibit a viscosity of at least 1,000 cP at the temperature at which the casting solution forms the film on the porous polymer support layer.
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
Methods of treating choroidal neovascularization in a patient in need thereof are described herein. In some aspects, the method comprises inhibiting telomerase activity within a biological compartment of the patient. In some instances, inhibiting telomerase activity comprises disposing a telomerase inhibitor and/or disposing an antisense oligonucleotide within the biological compartment of the patient. In some embodiments, the biological compartment of the patient is the eye. Further, in some instances, the patient has neovascular age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity (ROP), corneal neovascularization, and/or neovascular glaucoma.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
The present disclosure provides for a recombinant antibody targeting SSTR2, an antibody-drug conjugate, an antibody-radioisotope conjugate, and methods of using thereof.
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
93.
CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF
Disclosed are method of treating fibrotic conditions using carboranes and carborane analogs. Also disclosed herein are compounds comprising dicarba-closo-dodecaborane or a dicarba-closo-dodecaborane analog. The compounds can be, for example, estrogen receptor beta (ERβ) agonists. In some examples, the compounds can be selective ERβ agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof, by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
94.
LIGHT-INDUCED EXTRACELLULAR VESICLE AND PARTICLE ADSORPTION FOR LABEL-FREE CAPTURE AND QUANTIFICATION OF MOLECULAR CARGO
Disclosed are devices, systems, and methods related to the characterization and/or analysis of extracellular particles (EPs) and interactions therewith. The devices, systems, and methods can include a micropatterned substrate defining a binding region and a passivation region. The binding region includes a photoetched charged surface to non-specifically adsorb a population of EPs from a sample.
Systems and methods that automate the backup of specific patient related information to network attached, but segregated device. Each patient's information that is required for treatment (DICOM files) are automatically queried from the EHR databased and transferred using DICOM transactions to the workstation through specified TCP ports. The software automatically organizes and stores the files on a secure/encrypted USB drive. The software then leverages web-based application programming interfaces (APIs) to pull patient documents that are relevant for treatment. Finally, a treatment summary report is generated and stored along-side the EHR documents and DICOM files. In the event of a failure, the USB device can be removed and plugged into the treatment delivery devices to allow for treatment of patients under care.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
96.
ACTIVE FLOW CONTROL ENABLED VARIABLE AREA TURBINE VANE
A system may include a first blade and a second blade, each comprising an upper surface, a lower surface, a leading edge, and a trailing edge. The first blade and the second blade are spaced apart to define a throat area through which a fluid can flow. The device may include a first active flow control port disposed on the upper surface of the first blade and a second active flow control port disposed on the upper surface of the first blade closer to the trailing edge than the first active flow control port. The first and second active flow control ports are configured to inject a control fluid into the throat area to vary at least one of (i) a cross-sectional area of the fluid flowing through the throat area and (ii) an exit angle of the fluid leaving the throat area adjacent to the trailing edge.
F02C 9/18 - Commande du débit du fluide de travail par prélèvement, par bipasse ou par action sur des raccordements variables du fluide de travail entre des turbines ou des compresseurs ou entre leurs étages
97.
SYSTEMS AND METHODS FOR PREDICTING THROMBOSIS FOR HEART VALVE REPLACEMENTS
Methods for determining likelihood of thrombosis based on patient-specific anatomic, valve, and flow parameters are disclosed herein. Such methods are used to select a transcatheter aortic valve that decreases likelihood of thrombosis after TAVR procedures. The methods correlate a number of fluid flow and geometric parameters such as stasis volume, neo-sinus volume, kinematic viscosity, dynamic viscosity, heart rate, the circulation, ejection time, velocity of the main jet, wall shear stress, total kinetic energy in the neo sinus volume, width of the neo-sinus, height or depth of the neo-sinus, the angle between the velocity direction and the stent of the transcatheter valve, the distance from the tip of the leaflet perpendicular to the leaflet edge and intersecting the sinotubular junction, and the cross-sectional area of the neo-sinus taken from a longitudinal or axial perspective. Such parameters are used to derive empirical or semi-empirical mathematical models to determine the likelihood of thrombosis.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
98.
SYSTEM FOR AUTOMATED HIGH-SPEED IMAGING AND GENETIC MANIPULATION OF SMALL ANIMALS
A system includes an articulated robotic arm having a plate manipulator and an organism manipulator. A shelf array holds a plurality of plates within reach of the plate manipulator of the robotic arm. The shelf array includes plate shelves and lid shelves configured to retain plates and lids, respectively, including a first plate that holds a target organism. The system includes a working platform for organizing and supporting the plates on plate stations. The plate manipulator of the robotic arm is moveable to engage with the first plate to (i) remove the first plate from the first plate shelf, (ii) deposit the first lid from the first plate onto the first lid shelf, and (iii) move the first plate to a first plate station on the working platform without disengaging from the first plate. The organism manipulator can view and move organisms within the first plate.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12Q 1/24 - Méthodes d'échantillonnage, d'inoculation ou de développement d'un échantillonMéthodes pour isoler physiquement un micro-organisme intact
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
Described herein are methods to convert a carbohydrate-containing source to a carbonaceous product. In some aspects, the methods include contacting a first portion of the carbohydrate-containing source with a first inoculant comprising a LAB and acetogen, thereby forming a first fermentation mixture; incubating the first fermentation mixture to produce acetate; contacting a second portion of the carbohydrate-containing source with acetate and a second inoculant comprising a solventogenic Clostridia, thereby forming a second fermentation mixture which is incubated to produce the carbonaceous product. Also disclosed herein are fermentation inoculants for the conversion of a carbohydrate-containing source to a carbonaceous product, the inoculant comprising a LAB expressing an enzyme catalyzing the production of lactate from the source, a mixotrophic acetogen expressing an enzyme that catalyzes the production of acetate from lactate and formate, and a solventogenic Clostridia expressing an enzyme that catalyzes the production of the carbonaceous product from the carbohydrate source.
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
Disclosed herein are gene therapy vectors that are adipocyte-tropic (AAVRec2-BDNF or AAVRec2-NGF, for example) which can improve measurements of tissue innervation in neuropathic adipose tissue as well as platforms and kits for delivering the same. The disclosed platforms and kits can effectively deliver AAV-containing fluids subdermally across the subcutaneous adipose depot.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C07K 14/48 - Facteur de croissance des nerfs [NGF]
